Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten (CK-3773274) in Adults With Hypertrophic Cardiomyopathy (HCM)

You likely can't join if

• 1. Has received treatment with mavacamten: (a) within 56 days prior to dosing and (b) has not received approval for participation from the Medical Monitor.
• 2. Has participated in another investigational device or drug study or received an investigational device or drug < 1 month (or 5 half-lives for drugs, whichever is longer) prior to screening. Other investigational procedures while participating in this study are not permitted.
• 3. Since completion of a previous study of aficamten has: - Developed new-onset paroxysmal or permanent atrial fibrillation requiring rhythm restoring treatment (eg, direct-current cardioversion, ablation procedure, or antiarrhythmic therapy) < 30 days prior to screening. Patient may re-screen for CY 6022 after 30 days if heart rate < 100 bpm and/or rhythm is stable > 30 days. - Undergone septal reduction therapy (surgical myectomy or transcatheter alcohol ablation).
• 4. Had a confirmed LVEF < 40% with an associated dose interruption during participation in a prior study with aficamten.
• 5. History of implantable cardioverter-defibrillator (ICD) placement within 30 days prior to screening.